Press Release
AimedBio Signs Research Collaboration Agreement with AI Biomarker Company AIVIS, Accompanied by Strategic Investment
SEOUL, South Korea – AimedBio (CEO Nam-Gu Her) announced that it has signed a joint research agreement with AIVIS, a company specializing in AI-based digital pathology and biomarker analysis solutions, and has completed a strategic equity investment to bolster its competitiveness in ADC drug development. This collaboration aims to leverage AIVIS's "Qanti Discovery" platform to advance the pathology data generated during the ADC development process through AI-based quantitative analysis. The goal is to refine biomarker-centric patiention strategies and enhance the probability of clinical success.
AIVIS develops a platform that uses AI to analyze digital pathology images, quantify biomarker expression, and support clinical decision-making. Its flagship solution, ‘Qanti IHC,’ is an AI medical device that precisely analyzes immunohistochemistry (IHC) stained slides at the cellular level. It received approval as an in-vitro diagnostic medical device from the Ministry of Food and Drug Safety (MFDS) in September 2024 and has since been adopted by over 10 major hospitals in South Korea, contributing to the diagnostic accuracy of pathologists. AIVIS is also expanding the clinical application of its technology through licensing and collaborations with global companies like Philips and AstraZeneca.
Through this joint research, AimedBio plans to progressively automate its non-clinical and clinical pathology data analysis, improve the precision of patiention, and establish a foundation for an AI-based companion diagnostics (CDx) strategy.
"In the ADC era, AI-driven digital pathology and biomarker quantification are critical differentiating factors," said an official from AimedBio. "Through this partnership, we will strengthen our data-driven drug development framework and enhance our clinical development competitiveness."
-END-